Expanding Diagnostic Portfolio Immunodiagnostic Systems (IDS) continues to innovate with new immunoassays and automated analyzers, including recent launches of SARS-CoV-2 IgG and IgM tests, indicating a strong focus on expanding its product offerings that cater to infectious disease diagnostics and automation, presenting opportunities for sales of complementary diagnostics and lab automation solutions.

Integration and Growth Since its acquisition by Revvity and integration into Euroimmun, IDS has benefited from expanded resources and product synergies, creating opportunities to cross-sell advanced immunoassay solutions across global markets where Euroimmun has a strong presence.

Strategic Partnerships Collaborations with companies like Technogenetics for SARS-CoV-2 testing highlight IDS’s openness to strategic partnerships, paving the way for new joint offerings, co-marketing initiatives, and broader distribution channels in infectious and specialty testing markets.

Market Focus on Infectious Diseases The company’s recent development of SARS-CoV-2 antibody tests suggests a targeted approach toward infectious disease diagnostics, an area with increasing global demand, offering sales prospects for similar assays and related laboratory automation systems tailored for pandemic and endemic pathogens.

Global Market Position With a revenue range of up to $250 million and a sizable workforce, IDS’s position as a specialist in immunoassay technology in the UK and worldwide presents opportunities to introduce workflow enhancements, reagent kits, and related services to laboratories seeking to upgrade diagnostic capacities in a competitive market.